Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry.
Manaswini PillaiSimon ErridgeLara BapirMartha NicholasNishaanth DalavayeCarl HolveyRoss CoomberDaniela BarrosUrmila BhoskarGracia MwimbaKavita PraveenChris SymeonSimmi Sachdeva-MohanJames J RuckerMikael Hans SodergrenPublished in: Expert review of neurotherapeutics (2022)
Associated improvements in HRQoL were observed in patients who initiated CBMP therapy. Adverse events analysis suggests acceptability and safety up to 6 months. This study may inform randomized placebo-controlled trials, required to confirm causality and determine optimal dosing.